Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityNo recent work listed

Hao Zhang

Matched on ORCID iD 0000-0002-4582-2556; OpenAlex author ID A5100396913. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers

Papers 8

  1. Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1178966↗
  2. The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling. Co-author DOI 10.3390/cancers15225454↗
  3. Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis. Co-author DOI 10.1007/s00330-022-08698-3↗
  4. Long noncoding RNA LINC00261 upregulates ITIH5 to impair tumorigenic ability of pancreatic cancer stem cells. Last author DOI 10.1038/s41420-021-00575-0↗
  5. XGBoost Classifier Based on Computed Tomography Radiomics for Prediction of Tumor-Infiltrating CD8+ T-Cells in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.671333↗
  6. CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fonc.2021.707288↗
  7. Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK. Co-author DOI 10.3892/or.2016.4554↗
  8. Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells. Co-author DOI 10.3892/or.2015.3914↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yinghao Meng · 3 shared papers, 2021–2022 · strength 0.35
  2. Yun Bian · 3 shared papers, 2021–2022 · strength 0.35
  3. Jieyu Yu · 3 shared papers, 2021–2022 · strength 0.35
  4. Chengwei Shao · 3 shared papers, 2021–2022 · strength 0.35
  5. Jiancong Xie · 2 shared papers, 2023 · strength 0.34
  6. Qi Li · 2 shared papers, 2021–2022 · strength 0.24
  7. Jing Li · 2 shared papers, 2021 · strength 0.22
  8. Jianping Lu · 2 shared papers, 2021 · strength 0.22
  9. Li Wang · 2 shared papers, 2021 · strength 0.22
  10. Wenguang Peng · 1 shared paper, 2023 · strength 0.18
  11. Weidong Pan · 1 shared paper, 2023 · strength 0.18
  12. Tuo Hu · 1 shared paper, 2023 · strength 0.17
  13. Weidong Pan · 1 shared paper, 2023 · strength 0.17
  14. Tao Ma · 1 shared paper, 2023 · strength 0.17
  15. Jing Chen · 1 shared paper, 2023 · strength 0.17
  16. Lijuan Zou · 1 shared paper, 2021 · strength 0.16
  17. Jing Li · 1 shared paper, 2022 · strength 0.13
  18. Jianping Lu · 1 shared paper, 2022 · strength 0.13
  19. Chao Ma · 1 shared paper, 2021 · strength 0.11
  20. Kai Cao · 1 shared paper, 2021 · strength 0.11
  21. Hui Jiang · 1 shared paper, 2021 · strength 0.11
  22. Feng-Ping Pan · 2 shared papers, 2015–2016 · strength 0.10
  23. Heqi Bu · 2 shared papers, 2015–2016 · strength 0.10
  24. Shengzhang Lin · 2 shared papers, 2015–2016 · strength 0.10
  25. Liang Chen · 2 shared papers, 2015–2016 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.